NeuroPace enters $3.7M collaboration with Rapport for Phase 2a trial of RAP compound

NeuroPace Inc

Agreement with Rapport Therapeutics to support Phase 2a trial of GAMA 8 Receptor-Associated Protein (RAP) compound.
NeuroPace provides site data and monitoring capabilities for RNS System patients enrolled in the trial.
Agreement spans nine quarters (Q4 2023 to Q4 2025) with milestones, subject to early termination provisions.
Total anticipated revenue from collaboration is approximately $3.7 million, including a trial initiation payment in Q4 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

NeuroPace Inc entered into Agreement with Rapport Therapeutics, Inc. valued at approximately $3.7 million (effective 2023-11-28).

Action: entry
Agreement: collaboration
Counterparty: Rapport Therapeutics, Inc.
Value: approximately $3.7 million
Effective: 2023-11-28

Exact text from the filing

On November 28, 2023 NeuroPace, Inc. entered into a collaboration agreement (“Agreement”) with Rapport Therapeutics, Inc. (“Rapport”), pursuant to which NeuroPace will provide certain site data for Rapport to use in targeting potential patients for their Phase 2a trial of their GAMA 8 Receptor-Associated Protein (“RAP”) compound

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

NeuroPace Inc filing history →

Source: SEC EDGAR

accession 0001193125-23-288474

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.